Improvement in quality of life and angina pectoris: 1-year follow-up of patients with refractory angina pectoris and spinal cord stimulation

F. E. Vervaat · A. van der Gaag · H. van Suijlekom · C. J. Botman · K. Teeuwen · I. Wijnbergen

Published online: 19 May 2020
© The Author(s) 2020

Abstract
Aims Spinal cord stimulation (SCS) is a treatment for patients with refractory angina pectoris (RAP) who remain symptomatic despite optimal medical therapy and without revascularisation options. Previous studies have shown that SCS improves the quality of life in this patient group and reduces the severity of the angina pectoris. The aim of this prospective, single-arm observational study is to show this effect in a single-centre cohort using a multidisciplinary team approach to the selection process, with a follow-up period of 1 year.

Methods and results Between July 2010 and March 2017, 87 patients with RAP referred to our centre received SCS. The Seattle Angina Questionnaire (SAQ) and RAND 36-Item Health Survey (RAND-36) were completed at baseline, prior to implantation, and 1 year post-implantation. After 1 year of follow-up there was a statistically significant decrease in the frequency of angina pectoris attacks from more than 4 times a day to 1–2 times a week ($p<0.001$). The SAQ showed statistically significant improvement in four of the five dimensions: physical limitation ($p<0.001$), angina frequency ($p<0.001$), angina stability ($p<0.001$) and quality of life ($p<0.001$). The RAND-36 showed statistically significant improvement in all nine dimensions: physical functioning ($p=0.001$), role/physical ($p<0.001$), social functioning ($p=0.03$), role/emotional ($p<0.05$), bodily pain ($p<0.001$), general health ($p<0.001$), vitality ($p<0.001$), mental health ($p=0.02$) and health change ($p<0.001$).

Conclusion This study showed a significant improvement in quality of life and reduction of angina pectoris severity after 1 year of follow-up in patients treated with SCS for RAP.

Keywords Refractory angina pectoris · Spinal cord stimulation

Introduction
In recent decades, the evolution of medical therapy, coronary artery bypass grafting (CABG) and percutaneous coronary interventions (PCI) has significantly reduced the morbidity and mortality in patients presenting with stable coronary artery disease (CAD). Despite all these treatment innovations, 5–10% of patients with stable CAD remain symptomatic despite optimal therapy referred to as ‘refractory angina pectoris (RAP)’. This condition is defined as a ‘chronic condition (>3 months) characterised by diffuse CAD in the presence of proven ischaemia, which is not amendable to a combination of medical therapy, an-

What’s new?
- Improvement in quality of life and reduction in frequency of angina pectoris in patients with refractory angina pectoris and treatment with spinal cord stimulation.
- Uniform selection process with clear inclusion criteria performed by a multidisciplinary team.
spinal cord stimulation (SCS) is a treatment option that has been developed for patients with RAP to improve quality of life and reduce the frequency of angina pectoris episodes. Four possible mechanisms explaining the beneficial effects of SCS on RAP have been described: reduction of pain perception, decreased sympathetic tone, reduced myocardial oxygen demand and improved coronary microcirculatory blood flow [2, 3].

The number of trials regarding SCS in RAP published in recent years is limited. These studies showed an improvement in quality of life and a reduction in the severity of angina pectoris after SCS. However, evaluation of these studies revealed limitations which include methodological inconsistencies, heterogeneity in primary and secondary outcome measures and the inability to recruit sufficient numbers of patients to achieve significant statistical power to provide convincing and definitive conclusions [4–9].

The aim of this open, prospective, single-arm observational study, involving a multidisciplinary team during the selection process, is to show the effects of SCS on the severity of angina complaints and quality of life in a large, real-life single-centre cohort.

**Methods**

**Patient selection**

Patients referred to our hospital (Catharina Hospital Eindhoven, The Netherlands) with RAP were included if the following criteria were met: stable angina pectoris Canadian Cardiovascular Society (CCS) class III or IV for at least 3 months, significant CAD with no options for revascularisation (CABG and/or PCI) and optimal medical anti-angina therapy.

At the initial visit patients performed a symptom-inducing treadmill test to evaluate the effect of transcutaneous electrical nerve stimulation (TENS). Two electrodes were applied to the chest region and connected to a battery-operated TENS device (eco 2, Schwa-medico BV, Woudenberg, The Netherlands). The standard settings of the TENS device during the treadmill test were a pulse width of 200 µS (range 50–400 µS) and a frequency of 2 Hz (range 2–100 Hz). The treadmill (Enraf-Nonius BV, Rotterdam, The Netherlands) was started at 3.5 km/h, increasing the speed every 30s to a maximum of 5.5 km/h. When the maximum pace was reached the inclination angle increased by 1% every 30s until angina pectoris was induced. The TENS device was switched on and the amplitude turned up to 40 mA (maximum 100 mA). A timer was started to determine how quickly the symptoms disappeared after TENS initiation. The treadmill stress test was classified as TENS positive, dubious or negative. A TENS-positive test, i.e. resolution of angina pectoris more quickly than if short-acting nitroglycerin (NTG) was used, was an indication for implantation of a spinal cord stimulator. If the test was TENS dubious, i.e. resolution of angina pectoris as quickly as with the use of short-acting NTG, or TENS negative, i.e. no angina pectoris during the treadmill stress test, TENS was continued during 1 month and evaluated. If the patient benefitted from TENS after 1 month of use either implantation of a spinal cord stimulator or continuation with TENS were treatment options, depending on the wish of the patient. If the patient derived no benefit from TENS after 1 month treatment was stopped. During the initial visit the same team consisting of two interventional cardiologists, anaesthesiologist/pain specialist, physiotherapist and specialist pain nurse was present to evaluate the anamnesis and the results of the treadmill stress test performed by the patient.

**Implantation of SCS device**

Implantation of the SCS device is performed by the anaesthesiologist/pain specialist with the patient under sedation. Using a percutaneous approach the epidural compartment is accessed in the thoracic region. The lead is placed in the epidural space with the active part situated in the higher thoracic and lower cervical segments. The correct position of the lead is determined, with the sedation temporarily reduced, by using stimulations and the patient response. At the epidural entry point the lead is fixated and attached to an implantable pulse generator in the left buttock via a subcutaneous route. Both the entry site of the lead as well as the pulse generator pocket are closed, finishing the implantation procedure. In general the patients are able to leave the hospital the next day.

**Endpoints**

**Primary endpoints**

Quality of life and frequency of angina symptoms were the primary endpoints in this study. From patients who underwent SCS, data were collected using a general questionnaire (RAND 36-Item Health Survey [RAND-36]) and a disease-specific questionnaire (Seattle Angina Questionnaire [SAQ]). Patients were asked to complete these questionnaires at baseline, prior to implantation of the spinal cord stimulator, and 1 year after implantation. Both questionnaires have been validated for evaluating quality of life and the SAQ for evaluating severity of angina pectoris in patients with RAP and both have been used in other studies ([7, 10, 11]; Electronic Supplementary Material, Appendix 1). These questionnaires cannot be directly compared to each other since the SAQ is disease specific and the RAND-36 is a general health questionnaire.
Secondary endpoints

The secondary endpoints were use of short-acting nitrates (data collected from the SAQ) and clinical endpoints, including admission to the hospital due to chest pain and/or non-ST-elevation myocardial infarction (NSTEMI, defined as high sensitivity troponin T with at least one value above the 99th percentile and/or new ischaemic ECG changes and/or development of pathological Q waves), PCI due to NSTEMI or progressive stable angina pectoris at outpatient clinic follow-up, cardiovascular mortality and all-cause mortality during the follow-up period of 1 year. The last secondary endpoint were complications after the implantation of the spinal cord stimulator such as infection, lead and/or battery repositioning at 30 days and after 1-year follow-up. The data were collected by reviewing the patient files.

Statistical analysis

To analyse the results from the SAQ and RAND-36 questionnaires the paired Student's t-test was used. If the values were not normally distributed the Wilcoxon signed rank test was applied. Analysis was performed when both the baseline and 1-year data were available from the same patient. A probability value of <0.05 was considered statistically significant. All analysis was performed using SPSS version 23.0 for MacBook (SPSS, Inc., Chicago, IL, USA).

Results

Patient selection

From July 2010 through to March 2017, 127 patients who met the inclusion criteria for RAP were referred to our hospital. During the initial visit 126 patients performed a treadmill stress test. Of those, 87 patients had a TENS-positive test and therefore an indication for implantation of a spinal cord stimulator. Twenty-six patients had a TENS-dubious test and 13 patients a TENS-negative test with an indication for continuation of TENS during 1 month. A final num-

Table 1 Baseline patient characteristics

| Spinal cord stimulation (n=87) |
|-------------------------------|
| Age, years (mean ± SD) | 63.8 (±9.09) |
| Male (%) | 88.5 |
| CCS class III or IV (%) | 92.0 |
| Risk factors (%) | 85.5 |
| Positive family history of CVD | 52.9 |
| Active smoker | 13.8 |
| Hypertension | 95.4 |
| Hypercholesterolaemia | 97.7 |
| Diabetes | 39.1 |
| Myocardial infarction | 62.1 |
| Previous interventions (%) | |
| PCI | 83.9 |
| CABG | 82.8 |
| Medication use (%) | |
| Acetylsalicylic acid | 85.1 |
| P2Y12 inhibitor | 66.7 |
| OAC | 16.0 |
| Beta blocker | 85.1 |
| Dihydropyridines | 55.2 |
| Non-dihydropyridines | 11.5 |
| Ivabradine | 12.6 |
| ACE or ARB inhibitor | 71.3 |
| Diuretics | 29.9 |
| Statins | 94.3 |
| NTG short-acting | 86.2 |
| NIT long-acting | 81.6 |
| Spironolactone | 12.6 |
| Left ventricular ejection fraction (%) | |
| Normal (>50%) | 82.8 |
| Impaired (35–50%) | 11.5 |
| Reduced (<35%) | 3.4 |
| Miscellaneous (%) | |
| PM/ICD | 10.3 |
| Ischaemia | 69.0 |

*CCS Canadian Cardiovascular Society, CABG coronary artery bypass graft, PCI percutaneous coronary intervention, TENS transcutaneous electrical nerve stimulation, SCS spinal cord stimulation. aReasons for TENS instead of SCS: patient request (n=4), comorbidities (n=5), implantation of SCS device technically unsuccessful (n=2). bThis group of ten patients includes one patient who did not perform a treadmill stress test due to a lower leg amputation but received TENS during 1 month and continued with this treatment option*
Fig. 2  Results of Seattle Angina Questionnaire at baseline versus 1 year. (**p < 0.001)

Fig. 3 a,b Results of RAND 36-Item Health Survey at baseline versus 1 year. (*p < 0.05, **p < 0.001)
A total of 56 (64.4%) patients completed the questionnaire at baseline and at 1 year. One-year follow-up showed a statistically significant improvement in four of the five dimensions of the SAQ. The improvement in satisfaction with treatment was not statistically significant ($p=0.55$) (Fig. 2).

**RAND-36 questionnaire**

A total of 54 (62.1%) patients completed the questionnaire at baseline and at 1 year. One-year follow-up showed a statistically significant improvement in all nine dimensions of the RAND-36 (Fig. 3).

**Frequency of angina pectoris**

The frequency of angina pectoris attacks had decreased significantly from more than 4 times a day to 1–2 times a week at 1-year follow-up ($p<0.001$) (Fig. 4a).

**Secondary endpoints**

**Use of short-acting nitrates**

The use of short-acting nitrates due to angina pectoris had decreased significantly from 1–3 times a day to

---

**Fig. 4 One-year results of frequency of angina pectoris (a) and frequency of use of short-acting nitrates (b)**
Spinal cord stimulation (SCS) was indicated in 89 patients and a device was successfully implanted in 97.8% (n = 87) of these patients. In only two patients was the implantation not successful, and these patients continued with TENS.

During the follow-up period of 1 year a total of 16 patients were admitted to hospital due to chest pain, eight patients due to a NSTEMI and eight patients due to a non-cardiac cause of chest pain. Of the eight patients admitted to hospital due to a NSTEMI, four underwent a PCI and four were treated conservatively. Another six patients underwent PCI due to progressive angina pectoris during outpatient follow-up. Three patients died during the follow-up period, one of them due to a cardiovascular cause (Tab. 2).

**Clinical endpoints**

During the follow-up period of 1 year of follow-up two patients had to undergo repositioning of the lead position. In only two patients was the implantation not successful, and these patients continued with TENS. A standardised treadmill stress test was used to induce angina pectoris. The same TENS system with standardised settings was applied to treat the induced angina pectoris, and the team determined whether the test was positive, dubious or negative. Selection bias was minimised by protocolled screening and a symptom-inducing treadmill test executed by a multidisciplinary RAP team. This is in contrast to the most recent and largest study by Andrell et al. (from 2010), who included 121 patients from ten different centres [7]. In their study screening and selection process varied with each site, leading to possible selection bias.

The questionnaires used in the current study to evaluate quality of life and angina pectoris symptoms were the RAND-36 (general) and SAQ (disease specific). Although the percentages of complete follow-up of SAQ and RAND-36 (64.4 and 62.1% respectively) seem low, they are in line with those in the literature [12, 13]. All dimensions showed a statistically significant improvement at follow-up, with the exception of the dimension ‘treatment satisfaction’ of the SAQ, which encompasses how patients feel about their treatment in general and not specifically about the SCS treatment. The conclusion was that patients were already satisfied with the treatment they were receiving prior to being treated with SCS, leading to no significant improvement, and is in line with previous studies [3, 8, 14, 15].

One of the criteria in the definition of RAP was optimal anti-angina medication. Of our study population, 85.1% used beta blockers, 66.7% calcium antagonists, 81.6% long-acting and 86.2% short-acting nitrates. As many as 89.7% of the patients used at least two types of anti-angina medication (beta blocker, calcium antagonist and/or long-acting nitrate) and 48.3% used three types, confirming that optimal medical therapy was being received. This is comparable with other studies in patients with RAP.

In this study we included a high percentage of patients (69%) with ischaemia, as proven by MIBI-SPECT, which is important to avoid possible bias from patients with non-cardiac chest pain. Several RAP studies used reversible ischaemia (proven by MIBI-SPECT, ST-segment depression >0.1 mm during 48-h ambulatory ECG monitoring or exercise testing) as an inclusion criterion to recruit patients. However, the majority of these studies did not report the actual percentage of proven reversible ischaemia in the baseline data [3, 14–19]. Of those studies that did report the percentage of proven ischaemia, in the most recent and largest study by Andrell et al. it was 57% [7]. In this study subanalysis showed no difference as regards quality of life or angina pectoris between less than once a week at 1-year follow-up (p<0.001) (Fig. 4b).

**Table 2  Clinical endpoints**

| Clinical endpoints | Spinal cord stimulation (n = 87) |
|--------------------|---------------------------------|
| Hospital admissions for chest pain | 16 (18.4) |
| NSTEMI | 8 (9.2) |
| Non-cardiac cause | 8 (9.2) |
| Percutaneous coronary intervention | 10 (11.5) |
| NSTEMI | 4 (4.6) |
| Stable angina pectoris | 6 (6.9) |
| All-cause mortality | 3 (3.4) |
| Cardiovascular mortality | 1 (1.1) |
| Values are n (%) |
| NSTEMI non-ST-elevation myocardial infarction |

**Discussion**

The main findings of this study were a statistically significant improvement in the quality of life and a statistically significant reduction in the frequency of angina pectoris from more than 4 times a day to only 1–2 times a week in patients with RAP being treated with SCS during 1 year of follow-up. Secondary findings of this study were a significant reduction in the use of short-acting NTG use from 1–3 times a day to less than once a week, low cardiovascular mortality (1.1%) and low all-cause mortality (3.4%).

SCS was indicated in 89 patients and a device was successfully implanted in 97.8% (n = 87) of these patients. In only two patients was the implantation not successful, and these patients continued with TENS. The implantation procedure was safe with no complications occurring within 30 days of the implantation. During 1 year of follow-up two patients had to undergo a revision of the lead position.

This study was a large, single-centre, prospective observational study. All patients referred to our centre for treatment of RAP were evaluated by the same team. This team included two interventional cardiologists, an anaesthesiologist/pain specialist, a physiotherapist and a specialist pain nurse. A standardised treadmill stress test was used to induce angina pectoris. The same TENS system with standardised settings was applied to treat the induced angina pectoris, and the team determined whether the test was positive, dubious or negative. Selection bias was minimised by protocolled screening and a symptom-inducing treadmill test executed by a multidisciplinary RAP team. This is in contrast to the most recent and largest study by Andrell et al. (from 2010), who included 121 patients from ten different centres [7]. In their study screening and selection process varied with each site, leading to possible selection bias.

The questionnaires used in the current study to evaluate quality of life and angina pectoris symptoms were the RAND-36 (general) and SAQ (disease specific). Although the percentages of complete follow-up of SAQ and RAND-36 (64.4 and 62.1% respectively) seem low, they are in line with those in the literature [12, 13]. All dimensions showed a statistically significant improvement at follow-up, with the exception of the dimension ‘treatment satisfaction’ of the SAQ, which encompasses how patients feel about their treatment in general and not specifically about the SCS treatment. The conclusion was that patients were already satisfied with the treatment they were receiving prior to being treated with SCS, leading to no significant improvement, and is in line with previous studies [3, 8, 14, 15].

One of the criteria in the definition of RAP was optimal anti-angina medication. Of our study population, 85.1% used beta blockers, 66.7% calcium antagonists, 81.6% long-acting and 86.2% short-acting nitrates. As many as 89.7% of the patients used at least two types of anti-angina medication (beta blocker, calcium antagonist and/or long-acting nitrate) and 48.3% used three types, confirming that optimal medical therapy was being received. This is comparable with other studies in patients with RAP.

In this study we included a high percentage of patients (69%) with ischaemia, as proven by MIBI-SPECT, which is important to avoid possible bias from patients with non-cardiac chest pain. Several RAP studies used reversible ischaemia (proven by MIBI-SPECT, ST-segment depression >0.1 mm during 48-h ambulatory ECG monitoring or exercise testing) as an inclusion criterion to recruit patients. However, the majority of these studies did not report the actual percentage of proven reversible ischaemia in the baseline data [3, 14–19]. Of those studies that did report the percentage of proven ischaemia, in the most recent and largest study by Andrell et al. it was 57% [7]. In this study subanalysis showed no difference as regards quality of life or angina pectoris between
patients with and without proven ischaemia on MIBI-SPECT.

This was an open, prospective observational study, meaning that there was no control group. However, previous randomised controlled trials (RCTs) have had problems including sufficient patients, leading to small samples varying from 12 to 32 patients, specifically the two studies with a true control placebo group [8, 14]. There have been several studies comparing SCS treatment with other treatment options for RAP, but this does not represent a true control group. Also with SCS treatment it is difficult to perform a double-blind study because the patient can feel if the stimulations are present or not. To date the majority of the data with regard to the effect of SCS in patients with RAP has been provided by prospective observational studies and meta-analysis, which are important because of the difficulties in performing a methodologically sound RCT. The prospective observational studies that have been performed have shown a beneficial effect in reducing angina symptoms and improving quality of life. This includes the current prospective observational study, which is an important addition to the current knowledge of the effects of SCS because clear inclusion criteria and a uniform selection process by the same multidisciplinary team were used.

In this single-centre, prospective, single-arm observational study, involving a multidisciplinary team in the selection process, SCS treatment in patients with RAP significantly improved the quality of life during 1 year of follow-up. Furthermore, the frequency of angina pectoris episodes significantly decreased.

Conflict of interest EE. Vervaat, A. van der Gaag, H. van Suijlekom, C.J. Botman, K. Teeuwen and I. Wijnbergen declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mannheimer C, Camici P, Chester MR, et al. The problem of chronic refractory angina: report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J. 2002;23:355–70.

2. Latif OA, Nedenukovic SS, Stevenson LW. Spinal cord stimulation for chronic intractable angina pectoris: a unified theory on its mechanism. Clin Cardiol. 2001;24:533–41.

3. Eldabe S, Thomson S, Duarte R, et al. The effectiveness and cost-effectiveness of spinal cord stimulation for refractory angina (RASCAL study): a pilot randomized controlled trial. Neuromodulation. 2016;19:60–70.

4. De Jongste MJ, Haakasma J, Hautvast BW, et al. Effects of spinal cord stimulation on myocardial ischemia during daily life in patients with severe coronary artery disease. A prospective ambulatory electrocardiographic study. Br Heart J. 1994;71:413–8.

5. Hautvast BW, Blanksma PK, De Jongste MJ, et al. Effect of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris. Am J Cardiol. 1996;77:462–7.

6. Saraste A, Ukkonen H, Varis A, et al. Effect of spinal cord stimulation on myocardial perfusion reserve in patients with refractory angina pectoris. Eur Heart J Cardiovasc Imaging. 2015;16:449–55.

7. Andrell P, Yu W, Gersbach P, et al. Long-term effects of spinal cord stimulation on angina symptoms and quality of life in patients with refractory angina pectoris—results from the European Angina Registry Link Study (EARL). Heart. 2010;96:1132–6.

8. Eddicks S, Maier-Hauff K, Schenk M, et al. Thoracic spinal cord stimulation improves functional status and relieves symptoms in patients with refractory angina pectoris: the first placebo-controlled randomised trial. Heart. 2007;93:585–90.

9. Imran TE, Malapero R, Qavi AH, et al. Efficacy of spinal cord stimulation as an adjunct therapy for chronic refractory angina pectoris. Int J Cardiol. 2017;227:535–42.

10. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25:333–41.

11. Charlier L, Dutrannois J, Kaufman L. The SF-36 questionnaire: a convenient way to assess quality of life in angina pectoris patients. Acta Cardiol. 1997;52:247–60.

12. Baruch Y, Holtom BC. Survey response rate levels and trends in organizational research. Hum Relat. 2008;61:1139–60.

13. Cummings SM, Savitz LA, Konrad TR. Reported response rates to mailed physician questionnaires. Health Serv Res. 2001;35:1347–55.

14. Lanza GA, Grimaldi R, Greco S, et al. Spinal cord stimulation for the treatment of refractory angina pectoris: a multicenter randomized single-blind study (the SCS-ITA trial). Pain. 2011;152:45–52.

15. Zipes DP, Svorcikal N, Berman D, et al. Spinal cord stimulation therapy for patients with refractory angina who are not candidates for revascularization. Neuromodulation. 2012;15:550–8.

16. Mannheimer C, Eliasson T, Augustinsson LE, et al. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: the ESBY study. Circulation. 1998;97:1157–63.

17. Bondesson S, Pettersson T, Erdling A, et al. Comparison of patients undergoing enhanced external counterpulsation and spinal cord stimulation for refractory angina pectoris. Coron Artery Dis. 2008;19:627–34.

18. McNab D, Khan SN, Sharples LD, et al. An open-label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPIRIT trial. Eur Heart J. 2006;27:1048–53.

19. Di Pede F, Lanza GA, Zuin G, et al. Immediate and long-term clinical outcome after spinal cord stimulation for refractory stable angina pectoris. Am J Cardiol. 2003;91:951–5.